Representation of women is low for cardiovascular disease clinical trials in certain conditions.
Nebulized glycopyrrolate improves lung function and patient-reported outcomes in patients with moderate to very severe COPD.
Idarucizumab can effectively reverse the anticoagulant effect of dabigatran.
Low-dose levosimendan in addition to standard care did not result in lower 30-day mortality compared with placebo in patients requiring hemodynamic support post-cardiac surgery.
A positive phase 3 study showed that patients treated with LJPC-501 were likely to achieve pre-specified blood pressure targets vs placebo.